Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $212.00

Axsome Therapeutics (NASDAQ:AXSM) had its price target hoisted by Mizuho from $195.00 to $212.00 in a research report released on Wednesday,Benzinga reports. Mizuho currently has an outperform rating on the stock.

Several other equities analysts also recently issued reports on the stock. Wells Fargo & Company raised their price target on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. Robert W. Baird set a $132.00 target price on Axsome Therapeutics in a research report on Monday, February 3rd. Needham & Company LLC lifted their target price on Axsome Therapeutics from $133.00 to $153.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. Cantor Fitzgerald reissued an “overweight” rating and issued a $153.00 price target on shares of Axsome Therapeutics in a research note on Wednesday, February 19th. Finally, Truist Financial lifted their price objective on Axsome Therapeutics from $190.00 to $200.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. One analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $165.36.

Axsome Therapeutics Price Performance

Shares of AXSM opened at $127.54 on Wednesday. The business has a 50-day simple moving average of $104.27 and a two-hundred day simple moving average of $96.06. Axsome Therapeutics has a 12-month low of $64.11 and a 12-month high of $139.13. The stock has a market cap of $6.22 billion, a PE ratio of -21.29 and a beta of 1.05. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The company had revenue of $118.77 million during the quarter, compared to the consensus estimate of $117.83 million. Analysts anticipate that Axsome Therapeutics will post -2.79 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Nick Pizzie sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the transaction, the chief financial officer now directly owns 42,187 shares of the company’s stock, valued at approximately $5,529,450.09. This represents a 6.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 22.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Axsome Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Raiffeisen Bank International AG bought a new position in shares of Axsome Therapeutics in the 4th quarter worth $51,000. Assetmark Inc. bought a new position in shares of Axsome Therapeutics in the fourth quarter valued at $52,000. R Squared Ltd acquired a new position in shares of Axsome Therapeutics during the fourth quarter valued at about $64,000. Aquatic Capital Management LLC acquired a new position in shares of Axsome Therapeutics during the fourth quarter valued at about $76,000. Finally, GF Fund Management CO. LTD. bought a new stake in shares of Axsome Therapeutics during the fourth quarter worth about $86,000. Institutional investors own 81.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.